Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable
Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds
Three Organizations Publish Guideline For Biomarker Testing for Targeted Therapies
Avoiding Mediastinal Radiation Can Improve Patient Outcomes
Obese Men With Benign Biopsy At High Risk for Prostate Cancer
Ibrutinib Shows Disease Control In Elderly, High-Risk CLL Patients
Study Finds That CTC Was Used Correctly In Medicare Patients
ASCO Draft Recommendations Define Meaningful Trial Outcomes
Phase II Study Cohort Fails To Overcome Erlotinib Resistance
Alcohol Consumption Does Not Impact Survival of Breast Cancer
Study: Blood Test More Accurate Than Traditional Tumor Biopsy
European Treatment Regimen Less Toxic Than American Method
Study Finds Nearly Two-Thirds Of Children Return to Hospital Following Stem Cell Transplant
NCI CTEP Approved Trials For the Month of April
FDA Breakthrough Designation Granted to Pfizer’s Palbociclib
Trending Stories
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - In the Headlines: Missing record of NCAB meetings restored to NIH website
- Insights from ASCO 2025: Real-world evidence drives clinical decision-making
- In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”
